Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance resultsOctober 05, 2007MedImmune, Inc. today announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus (RSV). RSV is a viral pathogen that produces annual outbreaks usually between fall and spring. While RSV typically manifests cold-like symptoms in healthy children, it can prove to be a very serious respiratory illness for premature infants and is the leading cause of respiratory infections for newborns each year. MedImmune has long been committed to developing and improving products for prevention of RSV disease and to enhancing the body of knowledge about RSV epidemiology. "MedImmune continues to forge ahead with its aggressive strategy to help combat RSV disease," said Edward M. Connor, M.D., executive vice president and chief medical officer. "We are pleased to present new Phase 2 data at IDSA regarding motavizumab, a key investigational monoclonal antibody (MAb) within our product development portfolio that we are currently preparing for regulatory submission in the United States." Connor added, "We will also present data regarding RSV surveillance at IDSA. These data show regional variability of RSV in the community, particularly in the southernmost United States. We believe that a better understanding of the regional variation in the timing of RSV may help inform decisions about timing of RSV prophylaxis for children at risk for serious RSV disease."
Data pertaining to MedImmune's anti-RSV initiatives that will be presented during the IDSA meeting include: * Safety, Tolerability, and Immunogenicity of Motavizumab in Young Children After a Second Season of RSV Prophylaxis (Poster Presentation #233) - Katia G. Abarca, M.D., Infectious Diseases and Molecular Virology Laboratory, Universidad Católica de Chile, Friday, October 5, 2007; 12:30 - 2:00 p.m. in Poster Halls G-H. This study assessed the safety and immunogenicity of motavizumab, an investigational anti-RSV MAb, in young children with a history of prematurity who received two sequential seasons of the antibody. * RSV Surveillance: Retrospective and Current Data on the Variance in Season Onsets and Offsets (Poster Presentation #719) - Jessie R. Groothuis M.D., MedImmune, Saturday, October 6, 2007; 12:15 - 1:45 p.m. in Poster Halls G-H. A nationwide active surveillance program was established to evaluate the variability of the RSV season temporally and geographically in the United States. Laboratory results from a three-year period were analyzed by month and by geographic region. Edelman Public Relations | |||||||||||||||||||||
|
Related Infectious Disease Current Events and Infectious Disease News Articles Global warming link to amphibian declines in doubt Evidence that global warming is causing the worldwide declines of amphibians may not be as conclusive as previously thought, according to biologists. The findings, which contradict two widely held views, could help reveal what is killing the frogs and toads and aid in their conservation. Purdue researcher invents molecule that stops SARS A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease. Penn Scientists Show How Body Determines Optimal Amount of Germ-Fighting B Cells Researchers at the University of Pennsylvania School of Medicine can now explain how the body determines whether there are enough mature B-cells in the blood stream at any one time. These are the cells that produce antibodies against germs to fight infections. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. New molecules with many branches will help unleash potential of nanotechnology Materials science and the pharmaceutical industry could soon be revolutionized by emerging nanotechnologies based on designer molecules with long complex tree-and branch structures. Rapid HIV testing in the ER boosts diagnoses, screening One in every 50 people screened for a suspected sexually transmitted infection (STI) in the Emergency Department at Henry Ford Hospital was found to be infected with HIV using a rapid blood sample screening test. Vaccinating family members offers important flu protection to newborns Vaccinating new mothers and other family members against influenza before their newborns leave the hospital creates a "cocooning effect" that may shelter unprotected children from the flu, a virus that can be life-threatening to infants, according to researchers at Duke Children's Hospital. Avian flu threat: New approach needed As the first globally co-ordinated plan for the planet's gravest health threats is hatched by government ministers from around the world this weekend, a new report sets out a 10-point plan for this new, globalised approach to infectious diseases such as avian flu. X marks the spot: Sharpies get thumbs-up for marking surgery sites A bit of good news out of the Faculty of Medicine & Dentistry at the University of Alberta for patients undergoing surgery or an invasive procedure, their surgeons and cost-conscious hospital administrators. RNA molecules, delivery system improve vaccine responses, effectiveness A novel delivery system that could lead to more efficient and more disease-specific vaccines against infectious diseases has been developed by biomedical engineers at The University of Texas at Austin. More Infectious Disease Current Events and Infectious Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||